GAM Holding’s Crescent Biopharma CBIO Stock Holding History

GAM Holding’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-779	Closed	-$1.26M	–	905
2018 Q2	$1.26M	Hold	779	–	–	0.04%	402
2018 Q1	$1.26M	Buy	+779	New	+$1.62M	0.04%	395

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAM Holding's CBIO Position: Q3 2018 in Review

GAM Holding sold out of Crescent Biopharma (CBIO) in Q3 2018, closing a stake of 779 shares — an estimated $1.26M sold.

GAM Holding first reported a position in CBIO in Q1 2018 and held it in 2 quarters. The position peaked at $1.26M in Q1 2018. 85 funds tracked by Wall St. Rank hold CBIO as of Q3 2018.

GAM Holding reported no remaining Crescent Biopharma position as of Q3 2018 after selling out during the quarter.
GAM Holding sold 779 Crescent Biopharma shares in Q3 2018, an estimated $1.26M.
GAM Holding first reported a position in Crescent Biopharma in Q1 2018 and held it in 2 quarters.
GAM Holding's Crescent Biopharma position peaked at $1.26M in Q1 2018.
85 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2018.

Based on GAM Holding's 13F filing for Q3 2018, filed 13 Nov 2018.